Answers are grounded in this paper and cite their sources.
Peritoneal fibrosis (PF) represents a leading cause of long‐term peritoneal dialysis failure, yet effective therapies remain lacking. Macrophage polarization toward the pro‐inflammatory M1 phenotype is a key driver of fibrotic progression. FG‐4592, a clinically used hypoxia‐inducible factor prolyl hydroxylase inhibitor, has demonstrated potential anti‐inflammatory properties. However, its role and underlying mechanisms in peritoneal fibrosis are poorly understood. This study aimed to investigate whether FG‐4592 exerts therapeutic effects against peritoneal fibrosis by modulating macrophage polarization. We established a mouse model of peritoneal fibrosis induced by chlorhexidine gluconate (CG) and administered FG‐4592. Results showed that FG‐4592 treatment significantly attenuated epithelial‐mesenchymal transiion (EMT), collagen deposition, and peritoneal thickening. Furthermore, FG‐4592 effectively reduced macrophage infiltration into the peritoneum and suppressed macrophage polarization toward the M1 phenotype, evidenced by lowering both local and systemic levels of pro‐inflammatory cytokines (TNF‐α, IL‐6, IL‐1β) and nitric oxide (NO). In vitro experiments confirmed that FG‐4592 directly inhibited LPS/IFN‐γ‐induced M1 polarization of RAW264.7 macrophages and the release of inflammatory mediators, which was consistent with the in vivo results. Mechanistically, RNA‐seq analysis suggested the PI3K/AKT signaling pathway as a key target in the process of peritoneal fibrosis; FG‐4592 specifically suppressed phosphorylation‐mediated activation of this pathway. Crucially, the PI3K/AKT agonist 740 Y‐P reversed the inhibitory effect of FG‐4592 on M1 polarization. These findings indicate that FG‐4592 alleviates peritoneal fibrosis by inhibiting the PI3K/AKT pathway, thereby regulating M1 macrophage polarization and attenuating inflammatory responses. This study reveals a novel mechanism through which FG‐4592 counteracts peritoneal fibrosis and provides a new strategy for targeting macrophage in fibrotic diseases.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: